Kazda, Christof M <br/><br/>
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.  [electronic resource] 

 -  Diabetes care  11 2016 
 - e199-e200 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment 
<br/><br/><label>ISSN: </label>1935-5548 
<br/><br/><label>Standard No.: </label>10.2337/dci16-0030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Biphenyl Compounds<br/>Diabetes Mellitus, Type 2<br/>Glucagon<br/>Humans<br/>Receptors, Glucagon--antagonists & inhibitors